Literature DB >> 20512524

Differential response of two models of genetically modified mice fed with high fat and cholesterol diets: relationship to the study of non-alcoholic steatohepatitis.

Fernando Rodríguez-Sanabria1, Anna Rull, Gerard Aragonès, Raúl Beltrán-Debón, Carlos Alonso-Villaverde, Jordi Camps, Jorge Joven.   

Abstract

Research on the molecular basis of the hepatic alterations associated to obesity is dependent on the availability of suitable animal models. Apolipoprotein E deficient mice (ApoE(-/-)) and LDL-receptor deficient mice (LDLr(-/-)) develop steatosis and steatohepatitis when given pro-atherogenic diets. However, previous data suggest that these two models are not completely interchangeable, and that their metabolic phenotype may partially differ in response to nutrient stimuli. The present study further investigates this question, by comparing changes in hepatic inflammation, lipoprotein metabolism, and their related gene expressions. LDLr(-/-) mice were more susceptible to the development of obesity and hepatic steatosis, while the ApoE(-/-) model increased the amount of macrophages and inflammatory nodules in the liver. These changes were accompanied by a differential expression of selected members of the MAPK family and PPARs in the liver.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20512524     DOI: 10.1007/s11010-010-0498-2

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  28 in total

1.  The results in rodent models of atherosclerosis are not interchangeable: the influence of diet and strain.

Authors:  Jorge Joven; Anna Rull; Natàlia Ferré; Joan Carles Escolà-Gil; Judit Marsillach; Blai Coll; Carlos Alonso-Villaverde; Gerard Aragones; Joan Claria; Jordi Camps
Journal:  Atherosclerosis       Date:  2007-07-24       Impact factor: 5.162

2.  Feeding apolipoprotein E-knockout mice with cholesterol and fat enriched diets may be a model of non-alcoholic steatohepatitis.

Authors:  Mònica Tous; Natàlia Ferré; Jordi Camps; Francesc Riu; Jorge Joven
Journal:  Mol Cell Biochem       Date:  2005-01       Impact factor: 3.396

Review 3.  Cytokines, STATs and liver disease.

Authors:  Bin Gao
Journal:  Cell Mol Immunol       Date:  2005-04       Impact factor: 11.530

4.  Low-cholesterol and high-fat diets reduce atherosclerotic lesion development in ApoE-knockout mice.

Authors:  L Calleja; M A París; A Paul; E Vilella; J Joven; A Jiménez; G Beltrán; M Uceda; N Maeda; J Osada
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-10       Impact factor: 8.311

5.  Overexpression of c-myc in diabetic mice restores altered expression of the transcription factor genes that regulate liver metabolism.

Authors:  Efren Riu; Tura Ferre; Alex Mas; Antonio Hidalgo; Sylvie Franckhauser; Fatima Bosch
Journal:  Biochem J       Date:  2002-12-15       Impact factor: 3.857

6.  Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice.

Authors:  Petr Nachtigal; Nada Pospisilova; Gabriela Jamborova; Katerina Pospechova; Dagmar Solichova; Ctirad Andrys; Petr Zdansky; Stanislav Micuda; Vladimir Semecky
Journal:  Life Sci       Date:  2008-01-26       Impact factor: 5.037

Review 7.  Non-alcoholic fatty liver disease pathogenesis: the present and the future.

Authors:  S Petta; C Muratore; A Craxì
Journal:  Dig Liver Dis       Date:  2009-02-14       Impact factor: 4.088

Review 8.  Animal models of NASH: getting both pathology and metabolic context right.

Authors:  Claire Z Larter; Matthew M Yeh
Journal:  J Gastroenterol Hepatol       Date:  2008-08-21       Impact factor: 4.029

9.  Apolipoprotein E predisposes to obesity and related metabolic dysfunctions in mice.

Authors:  Iordanes Karagiannides; Rami Abdou; Aikaterini Tzortzopoulou; Peter J Voshol; Kyriakos E Kypreos
Journal:  FEBS J       Date:  2008-08-27       Impact factor: 5.542

10.  Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice.

Authors:  Xiaomei Qin; Xuefen Xie; Yanbo Fan; Jianwei Tian; Youfei Guan; Xian Wang; Yi Zhu; Nanping Wang
Journal:  Hepatology       Date:  2008-08       Impact factor: 17.298

View more
  6 in total

1.  Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis.

Authors:  Matthias Derwall; Rajeev Malhotra; Carol S Lai; Yuko Beppu; Elena Aikawa; Jasbir S Seehra; Warren M Zapol; Kenneth D Bloch; Paul B Yu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-01-05       Impact factor: 8.311

2.  Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver.

Authors:  Yu Li; Shanqin Xu; Amber Giles; Kazuto Nakamura; Jong Woo Lee; Xiuyun Hou; Gizem Donmez; Ji Li; Zhijun Luo; Kenneth Walsh; Leonard Guarente; Mengwei Zang
Journal:  FASEB J       Date:  2011-02-14       Impact factor: 5.191

Review 3.  Crossroads between peripheral atherosclerosis, western-type diet and skeletal muscle pathophysiology: emphasis on apolipoprotein E deficiency and peripheral arterial disease.

Authors:  Peggy Sfyri; Antonios Matsakas
Journal:  J Biomed Sci       Date:  2017-07-08       Impact factor: 8.410

Review 4.  Role of Cholesterol-Associated Steatohepatitis in the Development of NASH.

Authors:  Christian L Horn; Amilcar L Morales; Christopher Savard; Geoffrey C Farrell; George N Ioannou
Journal:  Hepatol Commun       Date:  2021-08-24

5.  2-heptyl-formononetin increases cholesterol and induces hepatic steatosis in mice.

Authors:  Charlotte Andersen; Janne G Schjoldager; Christian G Tortzen; Andreas Vegge; Majbritt R Hufeldt; Mette T Skaanild; Finn K Vogensen; Karsten Kristiansen; Axel K Hansen; John Nielsen
Journal:  Biomed Res Int       Date:  2013-04-29       Impact factor: 3.411

Review 6.  Understanding the Impact of Dietary Cholesterol on Chronic Metabolic Diseases through Studies in Rodent Models.

Authors:  Ángela Vinué; Andrea Herrero-Cervera; Herminia González-Navarro
Journal:  Nutrients       Date:  2018-07-21       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.